Uncategorized

The deal boosts BetterHelp’s ability to accept insurance coverage, offering “a potential avenue out of the less-stable cash pay market,” one analyst said.

Announcing first-quarter results, Biogen CEO Chris Viehbacher admitted that tariffs are “a new topic for us,” but said he does not expect major impacts—at least for 2025.

Cost pressures are “jeopardizing the ability of hospitals to deliver high-quality, timely care to their communities,” AHA CEO Rick Pollack said.

The new policy, revealed by the Department of Health and Human Services on Wednesday, would make vaccines “less available and less affordable,” according to vaccine expert Paul Offit. It could also further complicate the picture for companies like Novavax.

Jefferies analysts said Moderna’s first quarter was “in line,” with a miss on revenue offset by a beat on earnings per share.

Global employee engagement fell two percentage points in 2024, according to Gallup, while BioSpace found that workforce sentiment decreased among biopharma professionals. Additionally, a recent BioSpace poll suggests engagement could continue to decline in 2025.

To say, as CEO David Ricks did, that this was a good quarter, is an understatement. Mounjaro in diabetes brought in $3.84 billion for the quarter while Zepbound in weight loss booked $2.31 billion.

According to CEO Daniel Vitt, clinical and disability-related outcomes are more relevant than brain volume change for drug development in multiple sclerosis.

In another lawsuit against the HHS over the grant cuts, municipalities in Texas, Tennessee, Ohio and Missouri, as well as a labor union, argue eliminating the funding would weaken their ability to respond to infectious disease outbreaks, like measles.

The FDA has lost several senior employees in recent weeks, including some who have been at the agency for more than two decades.